List view / Grid view
After previous reports that nearly all spinal muscular atrophy (SMA)…
After previous reports that nearly all spinal muscular atrophy (SMA) patients treated with Zolgensma® achieved key motor milestones, Novartis announces publication of full SPR1NT results.
Asymptomatic and symptomatic children treated with Zolgensma® (onasemnogene abeparvovec) gene…
Asymptomatic and symptomatic children treated with Zolgensma® (onasemnogene abeparvovec) gene therapy achieved motor milestones never observed in the natural history of spinal muscular atrophy.
Treatment with Zolgensma® (onasemnogene abeparvovec) resulted in rapid and sustained…
Treatment with Zolgensma® (onasemnogene abeparvovec) resulted in rapid and sustained improvement in motor function in spinal muscular atrophy (SMA) patients.
